RxDoctor Payments Data

Marianne de Lima, MD

Neurology · Chandler, AZNPI 1346683794

Payments from drug & device makers

$30,023in general payments, 2019–2025

Across 652 payments — averaging $46.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • AbbVie$2K
  • Boston Scientific$1K
  • Acadia Pharmaceuticals Inc$815
  • Teva Pharmaceuticals USA, Inc.$735
  • Abbott$718
  • plus $8K from 51 others

What the payments were for

  • Speaking & faculty fees$400%
  • Grants$15,62552%
  • Travel & lodging$9283%
  • Food & beverage$13,23644%
  • Education$1941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)11$16,255
AbbVie(2 entities)100$1,800
Boston Scientific17$1,494
Acadia Pharmaceuticals Inc43$815
Teva Pharmaceuticals USA, Inc.27$735
Abbott16$718
UCB, Inc.56$697
Lilly USA, LLC35$643
Argenx US, Inc.24$628
Amgen(2 entities)43$574
Lundbeck LLC28$558
Amneal Pharmaceuticals LLC26$542
Pfizer27$456
Eisai Inc.18$440
Novartis22$395
AstraZeneca14$348
MDD US Operations, LLC14$283
Sanofi6$229
SK Life Science, Inc.8$200
Biogen8$158
Biohaven Pharmaceutical Holding Company Ltd.7$128
Merz Pharmaceuticals, LLC5$127
Neurocrine Biosciences, Inc.6$127
Avion Pharmaceuticals6$123
Kyowa Kirin, Inc.6$123
Acorda Therapeutics, Inc8$118
Jazz Pharmaceuticals Inc.3$91
Biohaven Pharmaceuticals, Inc.6$90
Otsuka America Pharmaceutical, Inc.4$76
Mallinckrodt Enterprises LLC3$74
Neurelis, Inc.4$73
Arbor Pharmaceuticals, Inc.3$72
Upsher-smith Laboratories LLC4$72
Alnylam Pharmaceuticals Inc.4$64
Axsome Therapeutics, Inc.2$63
Vertical Pharmaceuticals, LLC4$63
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$58
Sumitomo Pharma America, Inc.4$58
Mallinckrodt Hospital Products Inc.2$47
Sunovion Pharmaceuticals Inc.5$44
GE HealthCare2$33
Bristol Myers Squibb2$32
Collegium Pharmaceutical, Inc.2$28
CSL Behring1$25
Vanda Pharmaceuticals Inc.2$25
Supernus Pharmaceuticals, Inc.1$23
Harmony Biosciences LLC1$23
EMD Serono, Inc.1$23
Almatica Pharma LLC1$21
TG Therapeutics, Inc.1$20
Azurity Pharmaceuticals, Inc.1$18
Tonix Medicines, Inc.1$17
Johnson & Johnson1$17
Adamas Pharmaceuticals, Inc.1$16
Corium, LLC1$16
Avanir Pharmaceuticals, Inc.1$14
GRT US Holding, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,023 in reported general payments places this provider in the 70th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$184,356
Medicare patients
529
Services billed
3,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate63$490,659
BotoxOnabotulinumtoxina234$383,051
AustedoDeutetrabenazine31$303,329
RytaryCarbidopa/Levodopa72$98,825
InbrijaLevodopa20$65,323
XeominIncobotulinumtoxina40$62,992
UbrelvyUbrogepant39$50,696
NourianzIstradefylline11$39,147
GocovriAmantadine Hcl13$33,721
NuedextaDextromethorphan Hbr/Quinidine12$27,540
Aimovig AutoinjectorErenumab-Aooe36$25,855
Carbidopa-LevodopaCarbidopa/Levodopa627$23,880
OngentysOpicapone18$22,457
Emgality PenGalcanezumab-Gnlm19$17,274
NeuproRotigotine11$15,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$815$490,65963 claims
AbbVieBotox, Ubrelvy$1,800$433,748273 claims
Teva Pharmaceuticals USA, Inc.Austedo$735$303,32931 claims
Amneal Pharmaceuticals LLCRytary$542$98,82572 claims
Acorda Therapeutics, IncInbrija$118$65,32320 claims
Kyowa Kirin, Inc.Nourianz$123$39,14711 claims
MDD US Operations, LLCGocovri$283$33,72113 claims
Avanir Pharmaceuticals, Inc.Nuedexta$14$27,54012 claims
Neurocrine Biosciences, Inc.Ongentys$127$22,45718 claims
UCB, Inc.Neupro$697$15,23711 claims
Upsher-smith Laboratories LLCTopiramate$72$3,020198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 neurology providers in Arizona.

Other neurology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →